Neurológia pre prax 5/2025
New treatment options for myasthenia gravis
Myasthenia gravis is a serious autoimmune, antibody-mediated disorder of neuromuscular transmission. The condition is pathogenetically linked to thymic disease. It typically presents with skeletal muscle fatigability (including that of respiratory muscles) that fluctuates depending on fatigue and time of day. The diagnostic work-up is based on the clinical presentation, antibody testing, electrophysiology, and imaging of the thymus. Cholinesterase inhibitors are the main relief drugs. The essence of the pathogeneticallyoriented treatment is thymectomy and administration of corticosteroids and immunosuppressants. Currently, novel therapeutic strategies are beginning to be used in the treatment: C5 complement inhibitors and FcRn inhibitors. The use of strategies against B cell lines is still a subject of controversy or clinical trials.
Keywords: myasthenia gravis, treatment, complement inhibitors, FcRn inhibitors
